Cabozantinib a Viable Choice for Non-Clear Cell Renal Cell Carcinoma
There are no biomarkers ready that have been prospectively validated to help predict which patients with non-clear cell RCC might respond to cabozantinib.
Urologic Cancers
UROLOGIC CANCER ADVISOR
FEATURED CONTENT
-
-
Predicting PD-1/PD-L1 Immunotherapy Responses
Finding biomarkers that can broadly and reliably predict immunotherapy outcomes for patients with cancer remains an elusive “holy grail,” said Dr Ott. -
Thawing Frozen Cancer Drug Labels
As medical care rapidly evolves, there’s really no debate over the potential for drug labels to become outdated, particularly in the high stakes world of cancer treatment. The question is how best to ameliorate the problem, while still protecting the process from financial and other conflicts. Off-label prescribing of cancer drugs is common, occurring 30%… -
Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations
Concerns about conflict of interest as it relates to prescribing may never go away, some say, as long as drug companies offer doctors money for consulting and personal services. -
Opinion: Understanding the FDA’s Take on Cannabidiol
In a statement announcing a newly created partnership, the Botanical Safety Consortium, FDA Commissioner Scott Gottlieb made no mention of cannabidiol.
UROLOGIC CANCERS NEWS
High Monocyte-to-Lymphocyte Ratio Predictive of OS in Advanced Gallbladder Cancer
Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC
Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma
Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma
Want to read more?
Please login or register first to view this content.
Next post in General Oncology
